K. Urtishak

发表

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

E. Small, D. Rathkopf, D. Olmos, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

H. Scher, D. Danila, O. Ståhl, 2022, The Lancet. Oncology.